Open Access

Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast‑enhanced magnetic resonance imaging

  • Authors:
    • Jian Zhai
    • Wenqiang Zheng
    • Qin Zhang
    • Jiangfen Wu
    • Xuexi Zhang
  • View Affiliations

  • Published online on: February 28, 2019     https://doi.org/10.3892/ol.2019.10083
  • Pages: 4237-4244
  • Copyright: © Zhai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The value of pharmacokinetic parameters derived from dynamic contrast‑enhanced magnetic resonance imaging (DCE‑MRI) in distinguishing pituitary microadenoma subtypes was investigated in the present study. Pathology and follow‑up outcomes were applied as the gold standard for differentiating between 76 patients with pituitary microadenomas (38 prolactin‑producing tumors, 17 adrenocorticotropic hormone adenomas and 21 growth hormone‑producing tumors) and 20 patients with normal pituitary glands. DCE‑MRI was conducted to obtain the following quantitative permeability parameters: Volume transfer constant (Ktrans), rate constant (Kep) and extracellular extravascular volume fraction (Ve). Among the 76 cases included, 61 were visually diagnosed using conventional MRI. The Ktrans, Kep and Ve of the microadenoma cases were 0.472±0.292/min, 0.765±0.359/min and 0.792±0.345, respectively. The Ktrans, Kep and Ve of the normal control group were 0.902±0.238/min, 1.208±0.599/min and 0.928±0.378, respectively. The Ktrans and Kep of patients with microadenomas were significantly lower compared with those of the normal controls (P<0.05). However, the Ve of the two groups did not significantly differ. Subtype differentiation analysis revealed that patients with growth hormone‑producing tumors exhibited the highest Ktrans value (P<0.05). Kep significantly differed between growth hormone‑producing tumors and the other two subtypes (P<0.05), but did not significantly differ among three subtypes. Receiver‑operator characteristic analysis indicated that the area under the curve values of Ktrans and Kep were 0.884 and 0.728, respectively. Sensitivity and specificity were 95.0 and 82.6%, respectively, when Ktrans was set to 0.614/min as the cut‑off value, and when the Kep cut‑off value was set to 0.985/min, sensitivity and specificity were 60.0 and 81.3%, respectively. In conclusion, Ktrans and Kep derived from DCE‑MRI could be applied to detect and identify microadenoma subtypes. Ktrans better reflects the blood perfusion alterations exhibited by patients with different microadenoma subtypes.
View Figures
View References

Related Articles

Journal Cover

May-2019
Volume 17 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhai J, Zheng W, Zhang Q, Wu J and Zhang X: Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast‑enhanced magnetic resonance imaging. Oncol Lett 17: 4237-4244, 2019.
APA
Zhai, J., Zheng, W., Zhang, Q., Wu, J., & Zhang, X. (2019). Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast‑enhanced magnetic resonance imaging. Oncology Letters, 17, 4237-4244. https://doi.org/10.3892/ol.2019.10083
MLA
Zhai, J., Zheng, W., Zhang, Q., Wu, J., Zhang, X."Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast‑enhanced magnetic resonance imaging". Oncology Letters 17.5 (2019): 4237-4244.
Chicago
Zhai, J., Zheng, W., Zhang, Q., Wu, J., Zhang, X."Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast‑enhanced magnetic resonance imaging". Oncology Letters 17, no. 5 (2019): 4237-4244. https://doi.org/10.3892/ol.2019.10083